Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm

BACKGROUND: Hypertension (HTN) is the most frequent adverse event during treatment with lenvatinib (LEN), but data on its best management are limited. AIM: The objective of this study was to assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care centr...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Carla, Ceruti, Daniele, De Leo, Simone, Bilo, Grzegorz, Trevisan, Matteo, Giancola, Noemi, Moneta, Claudia, Parati, Gianfranco, Persani, Luca, Fugazzola, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308446/
https://www.ncbi.nlm.nih.gov/pubmed/37097040
http://dx.doi.org/10.1530/ETJ-23-0047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308446/
https://www.ncbi.nlm.nih.gov/pubmed/37097040
http://dx.doi.org/10.1530/ETJ-23-0047

Ejemplares similares